Serum neurofilaments increase at progressive multifocal leukoencephalopathy onset in natalizumab‐treated multiple sclerosis patients-Reference-Cited by-同舟云学术

Serum neurofilaments increase at progressive multifocal leukoencephalopathy onset in natalizumab‐treated multiple sclerosis patients

Published:2019-03-05 Issue:4 Volume:85 Page:606-610
ISSN:0364-5134
Container-title:Annals of Neurology
language:en
Short-container-title:Ann Neurol

Author:

Dalla Costa Gloria¹,Martinelli Vittorio¹,Moiola Lucia¹,Sangalli Francesca¹,Colombo Bruno¹,Finardi Annamaria²,Cinque Paola³,Kolb Eva‐Maria⁴,Haghikia Aiden⁴,Gold Ralf⁴,Furlan Roberto²,Comi Giancarlo¹

Affiliation:

1. Department of NeurologySan Raffaele Hospital Milan Italy

2. Neuroimmunology Research UnitRaffaele Hospital Milan Italy

3. Department of Infectious DiseasesSan Raffaele Hospital Milan Italy

4. Department of NeurologyRuhr University Bochum and St Josef Hospital Bochum Germany

Funder

Amici del Centro Sclerosi Multipla

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ana.25437

Reference22 articles.

1. A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis

2. Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

3. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases

4. Iatrogenic immunosuppression with biologics in MS: Expecting the unexpected?

5. Progressive ataxia in a natalizumab-treated multiple sclerosis patient: the dark side of JC virus infection

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Central Nervous System;Pathology of Non-Helminth Infectious Diseases;2024-09-01

2. Neuroaxonal damage in natalizumab-treated MS patients: The role of JCV antibody titres;Multiple Sclerosis Journal;2024-06-14

3. Biomarkers for progressive multifocal leukoencephalopathy: emerging data for use of JC virus DNA copy number in clinical trials;The Lancet Neurology;2024-05

4. Surrogate endpoints for progressive multifocal leukoencephalopathy;The Lancet Neurology;2024-05

5. Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer’s disease: a systematic review;Alzheimer's Research & Therapy;2024-04-27